Hilary Beck BA, PhD

Hilary After completing a Ph. D. at the University of Texas-Austin, Hilary Beck was an American Cancer Society Postdoctoral at the University of North Carolina-Chapel Hill. Hilary began her career at Amgen in 2005 and was an important member of the team that discovered AMG 232. In 2014, Hilary joined Flexus Biosciences as a Principal Investigator and served as a key leader in the discovery of the IDO inhibitor F001287, resulting the acquisition of Flexus by BMS. Afterward, Hilary was the project lead for the CCR program at FLX Bio. Hilary is currently a Director at IDEAYA Biosciences.